|
|
|
|
| | Creation of the Owen dermatology company in Dallas, Texas, USA. | | | Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas. | | | Nestlé acquires Alcon to strengthen its presence in the North American market. | | | L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology. | | | Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born. | | | Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products. | | | Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology. | | | Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom. | | | Acquisition of MetroGel®/Rozex® to include rosacea treatments in the product portfolio. | | | Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps. | | | Launch of anti-acne treatment Differin®, Galderma’s first home-grown dermatology product. | | | Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant. | | | Acquisition of Basotherm, a subsidiary of Germany’s Boehringer. | | | Inauguration of a new R&D facility in Princeton, New Jersey, USA. Acquisition in Brazil of Darrow’s dermatology portfolio. | | | Acquisition of Loceryl® (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed. | | | The Montreal production unit comes on stream. Launch of Silkis® (psoriasis) and acquisition of Capex® Shampoo (seborrheic dermatitis). | | | Licensing agreement for Metvix® (precancerous skin lesions and skin cancer treatment). Launch of Clindagel® (anti-acne). | | | Foundation stone laid for the new Research & Development Center in Sophia-Antipolis, France. Licensing agreements for Tri-Luma® (melasma or mask of pregnancy) and Pekiron® (Loceryl® Cream) in Japan. First FDA approvals for pharmaceutical production in Montreal. | | | Launch of Metvix® in Germany and the UK and Clobex® Lotion (inflammatory skin conditions) in the US. | | | Opening of a new production site in Hortolandia, Brazil. Clobex® Shampoo launch in the United-States and acquisition of Tri-Luma®. | | | Metrogel® 1% (rosacea) launch in the United-States. Galderma ranks Number One in D class in its markets (source : IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries). | | | Clobex® Spray launch in the US. Opening of the new R&D center in Sophia Antipolis, France. | | | In-licensing of Ipsen's Botulinum Toxin Type A for Europe, Argentina and Brazil. Differin® 0.3% launch. License agreements for Pliaglis® (topical anesthetic). | | | Launch of Pliaglis® and Epiduo® (acne). | | | Launch of Azzalure® (glabella lines) and Oracea® in Europe. Vertical®(psoriasis) launch in the United States. | | | Differin® Lotion 0.1% (acne) launch in the United States. | | | Creation of the Owen dermatology company in Dallas, Texas, USA. | | | Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas. | | | Nestlé acquires Alcon to strengthen its presence in the North American market. | | | L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology. | | | Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born. | | | Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products. | | | Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology. | | | Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom. | | | Acquisition of MetroGel®/Rozex® to include rosacea treatments in the product portfolio. | | | Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps. | | | Launch of anti-acne treatment Differin®, Galderma’s first home-grown dermatology product. | | | Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant. | | | Acquisition of Basotherm, a subsidiary of Germany’s Boehringer. | | | Inauguration of a new R&D facility in Princeton, New Jersey, USA. Acquisition in Brazil of Darrow’s dermatology portfolio. | | | Acquisition of Loceryl® (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed. | | | The Montreal production unit comes on stream. Launch of Silkis® (psoriasis) and acquisition of Capex® Shampoo (seborrheic dermatitis). | | | Licensing agreement for Metvix® (precancerous skin lesions and skin cancer treatment). Launch of Clindagel® (anti-acne). | | | Foundation stone laid for the new Research & Development Center in Sophia-Antipolis, France. Licensing agreements for Tri-Luma® (melasma or mask of pregnancy) and Pekiron® (Loceryl® Cream) in Japan. First FDA approvals for pharmaceutical production in Montreal. | | | Launch of Metvix® in Germany and the UK and Clobex® Lotion (inflammatory skin conditions) in the US. | | | Opening of a new production site in Hortolandia, Brazil. Clobex® Shampoo launch in the United-States and acquisition of Tri-Luma®. | | | Metrogel® 1% (rosacea) launch in the United-States. Galderma ranks Number One in D class in its markets (source : IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries). | | | Clobex® Spray launch in the US. Opening of the new R&D center in Sophia Antipolis, France. | | | In-licensing of Ipsen's Botulinum Toxin Type A for Europe, Argentina and Brazil. Differin® 0.3% launch. License agreements for Pliaglis® (topical anesthetic). | | | Launch of Pliaglis® and Epiduo® (acne). | | | Launch of Azzalure® (glabella lines) and Oracea® in Europe. Vertical®(psoriasis) launch in the United States. | | | Differin® Lotion 0.1% (acne) launch in the United States. | |
|
 |
|
|
|
|
|
|